- Characteristics and clinical outcome of T1 breast cancer: a . . .
Results Among 8100 women operated, 5423 had T1 tumors (708 T1a, 2208 T1b and 2508 T1c 11–15 mm) T1a differed significantly from T1b tumors with respect to several parameters (lower age, more frequent negative hormonal status and positive HER2 status, less frequent lymphovascular invasion), exhibiting a mix of favorable and poor prognosis factors Overall survival was not different between
- T1c Breast Cancer: Diagnosis, Treatment, and Prognosis
A T1c breast cancer diagnosis involves more than just tumor size Explore how individual biological factors guide a tailored approach to care and prognosis
- Understanding T1c Breast Cancer: Key Insights
Explore T1c breast cancer: definitions, diagnosis, treatments, and latest research advancements impacting patient outcomes 🔍💉 Learn more about this critical stage!
- Survival outcomes following upfront surgery vs neoadjuvant . . .
Survival outcomes following upfront surgery vs neoadjuvant chemotherapy for triple-negative and HER2-positive T1c and T2 breast cancer: A retrospective, population-based cohort study
- The survival benefit of adjuvant trastuzumab with or without . . .
The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer Kai C C Johnson,
- A survival analysis of T1 stage breast cancer and nomogram . . .
Therefore, the focus of current research has become clarifying the prognosis of T1a, T1b, and T1c breast cancer tumors, as well as assessing clinical and pathological features closely related to the prognosis of T1-stage tumors
- Survival outcomes of neoadjuvant versus adjuvant therapy in . . .
Survival outcomes of neoadjuvant versus adjuvant therapy in patients with T1c, node-negative, human epidermal growth factor receptor 2–positive breast cancer: A Surveillance, Epidemiology, and End Results population-based study
- Adjuvant capecitabine in early-stage triple-negative breast . . .
In addition, none of the patients in SYSUCC-001 received carboplatin in combination with a taxane, which has become the standard of care in early-stage triple-negative breast cancer, demonstrating improvements in pathological complete response, event-free survival, and overall survival in the neoadjuvant setting, in BrighTNess and other trials, 5,6
|